Insulet stock rises 7.57% but trails key competitors
Updated
Updated · MarketWatch · Apr 30
Insulet stock rises 7.57% but trails key competitors
5 articles · Updated · MarketWatch · Apr 30
Shares closed at $172.14 as the S&P 500 gained 1.02% and the Dow rose 1.62% in a broad market rally.
The gain ended a five-day losing streak, but Eli Lilly climbed 9.80%, while DexCom rose 3.46% and Johnson & Johnson added 1.10%.
Insulet remains 51.49% below its 52-week high of $354.88 reached on 20 November, while trading volume of 2.5 million topped its 50-day average of 1.0 million.
With a major product defect looming, is Insulet's stock rebound a sign of true recovery or a temporary illusion?
Will Insulet's product flaws give competitors a critical advantage in the race for next-generation diabetes technology?